Personalized vaccine plus immunotherapy shows promise for tough lung cancer

NCT ID NCT04487756

Completed Disease control Sponsor: Instituto Oncológico Dr Rosell Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab, then those who didn't worsen got the vaccine alongside atezolizumab as maintenance. The goal was to see if the combination is safe and improves 6-month progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (Tecentriq) and autologous dendritic cell vaccine
What this could lead to: If successful, this combination could help keep extensive-stage small cell lung cancer under control longer after initial chemotherapy, potentially improving survival.
What could go wrong: This is a small, early-phase trial (20 participants) with no control group, so results may not be generalizable. The vaccine is personalized and complex to produce, and side effects from the combination are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Hospital Clínic Barcelona

Barcelona, Barcelona, 08036, Spain
ICO Badalona

Badalona, Barcelona, 08916, Spain
Quirón Dexeus

Barcelona, Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.